Partnerships Pursue Drug Conjugation | Chemical & Engineering News
Volume 90 Issue 52 | p. 13 | Concentrates
Issue Date: December 24, 2012

Partnerships Pursue Drug Conjugation

Department: Business
Keywords: pharmaceuticals, antibody-drug conjugates, bispecific antibodies, drug conjugates

Celgene will make an undisclosed payment and take a stake in Sutro Biopharma as part of a collaboration to develop antibody-drug conjugates and bispecific antibodies against two undisclosed disease targets. Sutro, which says it could collect up to $500 million if the programs reach the market, will also manufacture a Celgene antibody. In a separate deal, Shire will work with Arrowhead Research to develop peptide-drug conjugates. In addition to research funding, Arrowhead could earn up to $33 million for each drug candidate developed.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment